The immunomodulatory effects of measles-mumps-rubella (MMR) vaccination on persistence of heterologous vaccine responses.
Citations
Altmetric:
Series / Report no.
Open Access
Type
Article
Language
en
Date
2019-02-21
Research Projects
Organizational Units
Journal Issue
Title
The immunomodulatory effects of measles-mumps-rubella (MMR) vaccination on persistence of heterologous vaccine responses.
Translated Title
Published in
Immunol Cell Biol 2019; 97(6):577-85
Abstract
It is proposed that measles-containing vaccines (MCV) have immunomodulatory effects which include a reduction in all-cause childhood mortality. The antibody response to heterologous vaccines provides a means to explore these immunomodulatory effects. This is the first study to investigate the influence of measles-mumps-rubella (MMR) vaccine on the persistence of antibodies to a broad range of heterologous infant vaccinations given in the first year of life. In total, 319 children were included in the study. All infants received routine vaccinations at 6 weeks, 4 and 6 months of age. At 12 months of age, 212 children were vaccinated with measles-mumps-rubella (MMR) and Haemophilus influenzae type b-meningococcus C (Hib-MenC) vaccine while the remaining 99 children had not yet received this vaccine. In the MMR/Hib-MenC-vaccinated group, blood was taken 28 ± 14 days after receiving these vaccines. Antibodies against diphtheria, tetanus, pertussis (pertussis toxin, filamentous haemagglutinin, pertactin), poliomyelitis (type 1, 2, 3) and 13 pneumococcal serotypes were measured. Geometric mean antibody concentrations (GMC) and seroprotection rates were compared between MMR/MenC-Hib-vaccinated and MMR/MenC-Hib-naïve participants. In the final analysis, 311 children were included. Seroprotection rates were lower in MMR/Hib-MenC-vaccinated children against pertussis toxin and pneumococcus serotype 19A. After adjustment for pre-specified factors, MMR/Hib-MenC-vaccinated infants had significantly higher antibody concentrations against tetanus (likely explained by a boosting effect of the carrier protein, a tetanus toxoid), while for the other vaccine antigens there was no difference in antibody concentrations between the two groups. This article is protected by copyright. All rights reserved.